{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:41:44Z","timestamp":1793421704678,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.crphar.2020.100012","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T01:27:51Z","timestamp":1609378071000},"page":"100012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal"],"prefix":"10.1016","volume":"2","author":[{"given":"Aditi","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Dalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarjun","family":"Rangaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Bala","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4363","authenticated-orcid":false,"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345791","article-title":"A\u00a0review: treatment of Alzheimer's disease discovered in repurposed agents","volume":"35","author":"Appleby","year":"2013","journal-title":"Dement. Geriatr. Cognit. Disord."},{"issue":"8","key":"10.1016\/j.crphar.2020.100012_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","article-title":"Drug repurposing in Parkinson's disease","volume":"32","author":"Athauda","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.crphar.2020.100012_bib3","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal \u03b1-synuclein aggregation in in vitro models of Parkinson's disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J.\u00a0Neurochem."},{"issue":"3","key":"10.1016\/j.crphar.2020.100012_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/14740330902859956","article-title":"Statins and the risk of Parkinson disease: an update on the controversy","volume":"8","author":"Becker","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.crphar.2020.100012_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00002018-200831050-00004","article-title":"Use of statins and the risk of Parkinson's disease","volume":"31","author":"Becker","year":"2008","journal-title":"Drug Saf."},{"issue":"17","key":"10.1016\/j.crphar.2020.100012_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/01.wnl.0000333215.93440.36","article-title":"Brain cholesterol metabolism and neurologic disease","volume":"71","author":"Benarroch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.crphar.2020.100012_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/frym.2018.00070","article-title":"What are neurodegenerative diseases and how do they affect the brain","volume":"6","author":"Berman","year":"2018","journal-title":"Front. Young Minds."},{"issue":"3","key":"10.1016\/j.crphar.2020.100012_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2710.2004.00560.x","article-title":"Do statins slow down Alzheimer's disease? A review","volume":"29","author":"Caballero","year":"2004","journal-title":"J.\u00a0Clin. Pharm. Therap."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JPD-171203","article-title":"Simvastatin as a potential disease-modifying therapy for patients with Parkinson's disease: rationale for clinical trial, and current progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J.\u00a0Parkinsons Dis."},{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(01)00529-9","article-title":"Use of statins in CNS disorders","volume":"187","author":"Cucchiara","year":"2001","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/17512433.2014.884923","article-title":"Repackaging FDA-approved drugs for degenerative diseases: promises and challenges","volume":"7","author":"Cummings","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.crphar.2020.100012_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.crphar.2020.100012_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","article-title":"Parkinson disease: from pathology to molecular disease mechanisms","volume":"62","author":"Dexter","year":"2013","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.crphar.2020.100012_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.freeradbiomed.2016.10.008","article-title":"Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease","volume":"101","author":"Doria","year":"2016","journal-title":"Free Radical Biol. Med."},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph11020044","article-title":"Old drugs as new treatments for neurodegenerative diseases","volume":"11","author":"Dur\u00e3es","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.crphar.2020.100012_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A\u00a0historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc. Jpn. Acad. Series B."},{"issue":"8","key":"10.1016\/j.crphar.2020.100012_bib17","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/00001756-199906030-00014","article-title":"The role of cholesterol in the biosynthesis of \u03b2-amyloid","volume":"10","author":"Frears","year":"1999","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1017\/S1461145701002310","article-title":"Treatment with controlled-release lovastatin decreases serum concentrations of human \u03b2-amyloid (A \u03b2) peptide","volume":"4","author":"Friedhoff","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11011-012-9343-5","article-title":"Effects of statins and cholesterol on memory functions in mice","volume":"27","author":"Ghodke","year":"2012","journal-title":"Metabolic Brain Dis"},{"issue":"43","key":"10.1016\/j.crphar.2020.100012_bib20","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"J.\u00a0Neurosci."},{"issue":"11","key":"10.1016\/j.crphar.2020.100012_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer's disease","volume":"16","author":"Goedert","year":"1993","journal-title":"Trends Neurosci."},{"issue":"6","key":"10.1016\/j.crphar.2020.100012_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects","volume":"8","author":"Golomb","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.crphar.2020.100012_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28089","article-title":"Dysregulated brain cholesterol metabolism is linked to neuroinflammation in huntington's disease","author":"Gonz\u00e1lez-Guevara","year":"2020","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1602\/neurorx.2.4.627","article-title":"New prospects and strategies for drug target discovery in neurodegenerative disorders","volume":"2","author":"Hilbush","year":"2005","journal-title":"NeuroRx"},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mds.26152","article-title":"Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study","volume":"30","author":"Huang","year":"2015","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.crphar.2020.100012_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.27609","article-title":"Brain cholesterol metabolism and Parkinson's disease","volume":"34","author":"Huang","year":"2019","journal-title":"Mov. Disord."},{"issue":"9242","key":"10.1016\/j.crphar.2020.100012_bib27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/009286150203600210","article-title":"505 (b)(2) applications: history, science, and experience","volume":"36","author":"Johnston","year":"2002","journal-title":"Drug Inf. J."},{"issue":"5","key":"10.1016\/j.crphar.2020.100012_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1210\/er.2011-1049","article-title":"Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver X receptors","volume":"33","author":"Kang","year":"2012","journal-title":"Endocrine Rev"},{"issue":"10","key":"10.1016\/j.crphar.2020.100012_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrneurol.2011.132","article-title":"Cholesterol metabolism in Huntington disease","volume":"7","author":"Karasinska","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.crphar.2020.100012_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2012.06.050","article-title":"Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms","volume":"1471","author":"Kumar","year":"2012","journal-title":"Brain Res."},{"issue":"1\u20133","key":"10.1016\/j.crphar.2020.100012_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.03.042","article-title":"Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats","volume":"709","author":"Kumar","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00365510802651858","article-title":"Oxysterols as markers of neurological disease\u2013a review","volume":"69","author":"Leoni","year":"2009","journal-title":"Scandinavian J. Clin. and Lab. Invest."},{"issue":"8","key":"10.1016\/j.crphar.2020.100012_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbalip.2014.12.018","article-title":"The impairment of cholesterol metabolism in Huntington disease","volume":"1851","author":"Leoni","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neulet.2005.11.046","article-title":"Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?","volume":"397","author":"Leoni","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.crphar.2020.100012_bib36","first-page":"2691","article-title":"Motor onset and diagnosis in Huntington disease using the diagnostic confidence level","volume":"262","author":"Liu","year":"2015","journal-title":"J.\u00a0Neurol."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728214.2012.672559","article-title":"Amyloid beta (A\u03b2) peptide modulators and other current treatment strategies for Alzheimer's disease (AD)","volume":"17","author":"Lukiw","year":"2012","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.crphar.2020.100012_bib38","doi-asserted-by":"crossref","first-page":"102107","DOI":"10.1016\/j.nano.2019.102107","article-title":"Nose-to-brain co-delivery of repurposed simvastatin and BDNF synergistically attenuates LPS-induced neuroinflammation","volume":"23","author":"Manickavasagam","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.crphar.2020.100012_bib40","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/0021-9150(95)96682-I","article-title":"The effect of simvastatin on cerebrospinal fluid levels of apolipoprotein E in patients with Alzheimer's disease","volume":"115","author":"Mitchel","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.crphar.2020.100012_bib41","series-title":"Statins in Multiple Sclerosis: a New Therapeutic Option?","author":"Neuhaus","year":"2003"},{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2005.03.030","article-title":"Putative mechanisms of action of statins in multiple sclerosis\u2013comparison to interferon-\u03b2 and glatiramer acetate","volume":"233","author":"Neuhaus","year":"2005","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.crphar.2020.100012_bib43","first-page":"1","article-title":"On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells","author":"Ntolkeras","year":"2019","journal-title":"Immunol. Res."},{"issue":"6","key":"10.1016\/j.crphar.2020.100012_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s004010000228","article-title":"DNA fragmentation, gliosis and histological hallmarks of Alzheimer's disease","volume":"100","author":"Overmyer","year":"2000","journal-title":"Acta Neuropathol."},{"issue":"8","key":"10.1016\/j.crphar.2020.100012_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","article-title":"Insights into computational drug repurposing for neurodegenerative disease","volume":"40","author":"Paranjpe","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neulet.2008.10.023","article-title":"Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease","volume":"448","author":"Patassini","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40263-015-0239-x","article-title":"Statin treatment in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Pihl-Jensen","year":"2015","journal-title":"CNS Drugs"},{"issue":"20","key":"10.1016\/j.crphar.2020.100012_bib48","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","article-title":"Neurodegenerative diseases and prions","volume":"344","author":"Prusiner","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JAD-2010-101653","article-title":"Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment","volume":"24","author":"Ramirez","year":"2011","journal-title":"J.\u00a0Alzheim. Dis."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib50","first-page":"16","article-title":"Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11011-017-0021-5","article-title":"The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration","volume":"32","author":"Saravi","year":"2017","journal-title":"Metabolic Brain Dis"},{"issue":"6","key":"10.1016\/j.crphar.2020.100012_bib52","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fund. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.crphar.2020.100012_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mds.27591","article-title":"Statin use and delayed onset of Huntington's disease","volume":"34","author":"Schultz","year":"2019","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1399-0004.2006.00668.x","article-title":"Predictive testing for Huntington disease: interpretation and significance of intermediate alleles","volume":"70","author":"Semaka","year":"2006","journal-title":"Clin. Genet."},{"key":"10.1016\/j.crphar.2020.100012_bib57","first-page":"754","article-title":"Therapeutic potential of lovastatin in multiple sclerosis","author":"Sena","year":"2003","journal-title":"J.\u00a0Neurol."},{"issue":"5391","key":"10.1016\/j.crphar.2020.100012_bib58","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1126\/science.282.5391.1072","article-title":"Experimental therapeutics of neurodegenerative disorders: unmet needs","volume":"282","author":"Shoulson","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.crphar.2020.100012_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res"},{"issue":"3\u20134","key":"10.1016\/j.crphar.2020.100012_bib60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ddstr.2011.06.008","article-title":"Repositioned drugs: integrating intellectual property and regulatory strategies","volume":"8","author":"Smith","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"1","key":"10.1016\/j.crphar.2020.100012_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0925-4439(00)00040-5","article-title":"Oxidative stress in Alzheimer's disease","volume":"1502","author":"Smith","year":"2000","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib62","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J.\u00a0Cell. Mole. Med."},{"key":"10.1016\/j.crphar.2020.100012_bib63","first-page":"49","article-title":"Drugs and clinical trials in neurodegenerative diseases","volume":"47","author":"Stanzione","year":"2011","journal-title":"Annali dell'Istituto superiore di sanit\u00e0"},{"issue":"3","key":"10.1016\/j.crphar.2020.100012_bib64","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/jpet.105.094136","article-title":"Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin","volume":"316","author":"Thelen","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"20","key":"10.1016\/j.crphar.2020.100012_bib65","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"JACC (J. Am. Coll. Cardiol.)"},{"issue":"7","key":"10.1016\/j.crphar.2020.100012_bib66","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"43","key":"10.1016\/j.crphar.2020.100012_bib67","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","article-title":"Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease","volume":"25","author":"Valenza","year":"2005","journal-title":"J.\u00a0Neurosci."},{"issue":"9421","key":"10.1016\/j.crphar.2020.100012_bib68","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.crphar.2020.100012_bib69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"issue":"12","key":"10.1016\/j.crphar.2020.100012_bib70","article-title":"Statins for multiple sclerosis","author":"Wang","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.crphar.2020.100012_bib71","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.crphar.2020.100012_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jneuroim.2006.06.006","article-title":"Statins in the treatment of central nervous system autoimmune disease","volume":"178","author":"Weber","year":"2006","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"3\u20134","key":"10.1016\/j.crphar.2020.100012_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ddstr.2011.06.007","article-title":"Intellectual property and other legal aspects of drug repurposing","volume":"8","author":"Witkowski","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"10","key":"10.1016\/j.crphar.2020.100012_bib74","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.crphar.2020.100012_bib75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein & cell"},{"issue":"3","key":"10.1016\/j.crphar.2020.100012_bib76","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.neuroscience.2010.02.054","article-title":"Lovastatin improves neurological outcome after nucleus basalis magnocellularis lesion in rats","volume":"167","author":"Zhao","year":"2010","journal-title":"Neuroscience"}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257120300146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257120300146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:59:43Z","timestamp":1762923583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257120300146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":76,"alternative-id":["S2590257120300146"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2020.100012","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2020.100012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100012"}}